Reconnecting

The current page stays visible while onset.to reconnects in the background.

onset.to

← All weeks

Highlights Jul 6 - Jul 12, 2026

new every Sunday

Clinical development defined the week, with early studies extending psychedelic treatment research into anorexia, postpartum depression, migraine, and oral ketamine. Oregon's evolving rules and newly detected LSD analogues showed policy and harm reduction moving alongside the science.

  1. 01 Psilocybin therapy for adult females with anorexia nervosa: pilot study in The British Journal of Psychiatry assessing feasibility, safety and early clinical signals

    A pilot study found psilocybin therapy feasible and acceptably safe for women with anorexia, with preliminary signs of benefit.

    cambridge.org · Jul 8, 2026 Psilocybin Research
  2. 02 Luvelsilocin enters FDA trials as a fast-acting psilocybin-derived treatment candidate for postpartum depression with effects designed to fit a short therapeutic window

    Luvelsilocin entered FDA-cleared testing for postpartum depression, pairing rapid action with a shorter psychoactive window.

    psypost.org · Jul 10, 2026 Psilocybin Clinical
  3. 03 Psychedelic use is linked to a lower likelihood of migraines in a twin study, with within-pair analyses suggesting the association is not fully explained by shared genetics or family environment

    A twin study linked psychedelic use to lower migraine likelihood, including within-pair results that reduce some familial confounding.

    psypost.org · Jul 10, 2026 Unspecified Research
  4. 04 Oregon's psilocybin program faces major regulatory changes as Senate Bill 303 advances and the state's first licensed service centers navigate implementation

    Oregon's SB 303 could reshape facilitator requirements, service-center operations, and the durability of regulated psilocybin access.

    themicrodose.substack.com · Jul 10, 2026 Psilocybin Policy
  5. 05 1Bz-LSD und 1-TMSBz-LSD markieren den erstmaligen Nachweis zweier neuartiger LSD-Derivate in Japan und zeigen die fortlaufende Ausdifferenzierung des LSD-Analogenmarkts

    Japan's first detections of 1Bz-LSD and 1-TMSBz-LSD show how quickly new analogues can outpace monitoring and harm reduction.

    psychedelia-stiftung.de · Jul 9, 2026 LSD Research
  6. 06 Neue Ketamin-Tablette zeigt in ersten Daten wenige Nebenwirkungen, doch Nutzen und Risiken einer Langzeitbehandlung bei Depressionen bleiben noch unklar

    Early oral ketamine data suggest few acute side effects, but long-term antidepressant benefits and risks remain unresolved.

    psychedelia-stiftung.de · Jul 7, 2026 Ketamine Clinical